# Dose Finding Study for Combination of Capecitabine, Lapatinib and Vinorelbine in Metastatic Breast Cancer

> **NCT01238029** · PHASE1 · TERMINATED · sponsor: **Sponsor GmbH** · enrollment: 12 (actual)

## Conditions studied

- Metastatic Breast Cancer
- HER2 Positive
- First or Second Line Therapy
- Failure or Contraindication of Trastuzumab Therapy

## Interventions

- **DRUG:** Lapatinib and Capecitabine and Vinorelbine

## Key facts

- **NCT ID:** NCT01238029
- **Lead sponsor:** Sponsor GmbH
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2010-10
- **Primary completion:** 2014-07
- **Final completion:** 2014-07
- **Target enrollment:** 12 (ACTUAL)
- **Why stopped:** new methods of treatment, no more patients appilicable for study
- **Last updated:** 2014-11-21

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01238029

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01238029, "Dose Finding Study for Combination of Capecitabine, Lapatinib and Vinorelbine in Metastatic Breast Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01238029. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*